2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02794857 (ClinicalTrials.gov) | August 29, 2016 | 24/5/2016 | Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation | Amyotrophic Lateral Sclerosis | Drug: NP001;Drug: Placebo | Neuraltus Pharmaceuticals, Inc. | NULL | Completed | 21 Years | 80 Years | All | 138 | Phase 2 | United States;Canada |
| 2 | NCT01281631 (ClinicalTrials.gov) | February 2011 | 17/1/2011 | A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: NP001;Drug: Placebo | Neuraltus Pharmaceuticals, Inc. | NULL | Completed | 21 Years | 80 Years | Both | 136 | Phase 2 | United States |
| 3 | NCT01091142 (ClinicalTrials.gov) | July 2010 | 19/3/2010 | Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS) | Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: NP001;Drug: Placebo | Neuraltus Pharmaceuticals, Inc. | NULL | Completed | 21 Years | 75 Years | Both | 56 | Phase 1 | United States |